DexCom (DXCM) PT Raised to $270 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $82.97 -2.11%
Rating Summary:
33 Buy, 7 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
33 Buy, 7 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Morgan Stanley analyst David Lewis raised the price target on DexCom (NASDAQ: DXCM) to $270.00 (from $225.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- TeamViewer (TMV:GR) (TMVWY) PT Lowered to EUR6.50 at Deutsche Bank
- Gerresheimer AG (GXI:GR) (GRRMF) PT Raised to EUR28 at Deutsche Bank
- DexCom (DXCM) PT Raised to $97 at Canaccord
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
